{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:15:34Z","timestamp":1790129734563,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in patients with poor performance status owing to their high efficacy and safety. The third-generation EGFR-tyrosine kinase inhibitor osimertinib has demonstrated effectiveness in the initial treatment of advanced EGFR mutation-positive non-small cell lung cancer in patients with good performance status; however, no evidence exists of the drug\u2019s effectiveness in patients with poor performance status in a prospective study. We designed a study that aims to investigate the efficacy and safety of first-line osimertinib treatment in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations and with poor performance status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The OPEN\/TORG2040 study is a multicenter, single-arm, phase II trial for patients with unresectable, advanced EGFR mutation-positive non-small cell lung cancer with a poor performance status (\u2265 2). Eligible patients will receive osimertinib until disease progression or unacceptable toxicity. The primary endpoint is the objective response rate of the first-line osimertinib treatment. Considering a threshold value of 45%, expected value of 70% for objective response rate, one-sided significance level of 5%, statistical power of 80%, and ineligible patients, the sample size was set to 30. The secondary endpoints are disease control rate, performance status improvement rate, and safety and patient-reported outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Quality of Life Questionnaire and Lung Cancer 13. Time to treatment failure, progression-free survival, and overall survival will also be assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Our study can determine the clinical benefits of osimertinib treatment in patients with poor performance status, since the clinical outcomes of patients with EGFR mutation-positive non-small cell lung cancer with poor performance status treated with this drug as a first-line treatment have not been sufficiently evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Japan Registry of Clinical Trials: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/\">jRCTs041200100<\/jats:ext-link> (registration date: February 12, 2021).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10409-6","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:03:19Z","timestamp":1671091399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN\/TORG2040)"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-4401","authenticated-orcid":false,"given":"Tomoya","family":"Fukui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiichiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki I.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Naoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"10409_CR1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129\u201339.","journal-title":"N Engl J Med"},{"key":"10409_CR2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science."},{"key":"10409_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"10409_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107:1179\u201386.","journal-title":"Cancer Sci"},{"key":"10409_CR5","doi-asserted-by":"publisher","first-page":"23874","DOI":"10.18632\/oncotarget.8074","volume":"7","author":"B Lee","year":"2016","unstructured":"Lee B, Lee T, Lee S-H, Choi YL, Han J. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget. 2016;7:23874\u201384.","journal-title":"Oncotarget."},{"key":"10409_CR6","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA J\u00e4nne","year":"2015","unstructured":"J\u00e4nne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689\u201399.","journal-title":"N Engl J Med"},{"key":"10409_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361.","journal-title":"Cancer Discov"},{"key":"10409_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"10409_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyy179","volume":"49","author":"Y Ohe","year":"2019","unstructured":"Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019;49:29\u201336.","journal-title":"Jpn J Clin Oncol"},{"key":"10409_CR10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","volume":"9","author":"KS Albain","year":"1991","unstructured":"Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience. J Clin Oncol. 1991;9:1618\u201326.","journal-title":"J Clin Oncol"},{"key":"10409_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","volume":"13","author":"M Paesmans","year":"1995","unstructured":"Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung Cancer working party. J Clin Oncol. 1995;13:1221\u201330.","journal-title":"J Clin Oncol"},{"key":"10409_CR12","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","volume":"177","author":"S Kudoh","year":"2008","unstructured":"Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177:1348\u201357.","journal-title":"Am J Respir Crit Care Med"},{"key":"10409_CR13","doi-asserted-by":"crossref","unstructured":"Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.\u00a0Lancet Oncol.\u00a02012;13:1161\u201370.","DOI":"10.1016\/S1470-2045(12)70412-6"},{"key":"10409_CR14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","volume":"27","author":"A Inoue","year":"2009","unstructured":"Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394\u2013400.","journal-title":"J Clin Oncol"},{"key":"10409_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyz041","volume":"49","author":"K Nakashima","year":"2019","unstructured":"Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, et al. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol. 2019;49:671\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"10409_CR16","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.21037\/jtd.2019.06.03","volume":"11","author":"Y Kato","year":"2019","unstructured":"Kato Y, Hosomi Y, Watanabe K, Yomota M, Kawai S, Okuma Y, et al. Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 2019;11:2350\u201360.","journal-title":"J Thorac Dis"},{"key":"10409_CR17","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s10637-020-00943-0","volume":"38","author":"K Nakashima","year":"2020","unstructured":"Nakashima K, Ozawa Y, Daga H, Imai H, Tamiya M, Tokito T, et al. Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investig New Drugs. 2020;38:1854\u201361.","journal-title":"Investig New Drugs"},{"key":"10409_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s10147-021-02043-2","volume":"27","author":"Y Tsubata","year":"2022","unstructured":"Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, et al. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022;27:112\u201320.","journal-title":"Int J Clin Oncol"},{"key":"10409_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/sj.bjc.6603710","volume":"96","author":"M Satouchi","year":"2007","unstructured":"Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer. 2007;96:1191\u20136.","journal-title":"Br J Cancer"},{"key":"10409_CR20","first-page":"5057","volume":"33","author":"Y Okuma","year":"2013","unstructured":"Okuma Y, Hosomi Y, Nagamata M, Yamada Y, Sekihara K, Kato K, et al. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Anticancer Res. 2013;33:5057\u201364.","journal-title":"Anticancer Res"},{"key":"10409_CR21","doi-asserted-by":"crossref","unstructured":"Igawa S, Fukui T, Kasajima M, Ono T, Ozawa T, Kakegawa M, et al. First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.\u00a0Investig.\u00a02021;40:430\u20137.","DOI":"10.1007\/s10637-021-01195-2"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10409-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10409-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10409-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:04:48Z","timestamp":1671091488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10409-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10409"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10409-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The National Hospital Organization Nagoya Medical Center Certified Review Board of Clinical Research approved this protocol on December 21, 2020 (approval number: C2020-010). This clinical trial was registered in the Japan Registry of Clinical Trials (registered date: 12 February 2021, registry number: jRCTs041200100). Written informed consent was obtained from all the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is conducted with financial support from AstraZeneca K.K.TF received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd., and honoraria from Nippon Kayaku Co. Ltd. and Pfizer Japan Inc. JS received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Bayer Yakuhin Co. Ltd., Kyowa Hakko Kirin Co. Ltd., MSD Co. Ltd., Nippon Kayaku Co. Ltd., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Taiho Pharmaceutical Co. Ltd.; research funding from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd.; and consulting or advisory fees from A2 Healthcare Corp. SI received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., and research funding from Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., and Nippon Kayaku Co. Ltd. YK received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., and Taiho Pharmaceutical Co. Ltd., and research funding from MSD K.K. HO received lecture fees from Astellas Pharma Inc., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Novartis Pharma K.K., and MSD K.K., and research funding from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Merck BioPharma Co. Ltd., and Taiho Pharmaceutical Co. Ltd. KN received lecture fees from AstraZeneca K.K., Boehringer-Ingelheim Japan Inc., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co. Ltd., and Taiho Pharmaceutical Co. Ltd. AK and TIS declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1314"}}